Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
Inc. Magazine Announces Its 27th Annual List of America’s 5000 Fastest-Growing Private Companies
Colorado Springs, Colo. August 28, 2008– Inc. magazine ranked Coast Independent Review Board No. 2356 on its 27th annual Inc. 5000 list of the fastest-growing private companies in the U.S.
As an Inc. 5000 honoree, Coast Independent Review is now a member of the most influential business clubs in America. The company you keep is notable, as Inc. 5000 alumni include Bill gates of Microsoft, Larry Ellison of Oracle, and many more. The Inc. 5000 is ranked according to percentage revenue growth from 2004 through 2007.
Coast Independent Review Board (IRB) safeguards the rights and well-being of clinical research trial participants for Phase I-IV pharmaceutical, medical device and repository trials. Coast IRB’s associates focus on the customer. “We continue to look for new ways to keep our customer relationships central to our process,” states Darren McDaniel Founder & Managing Director. Additionally, McDaniel promotes educational opportunities to help improve the standards in the industry. This month Coast IRB sponsored a contest to test the ethical savvy of clinical associates. Coast will continue to renovate progress with in the industry by promoting ethical reforms. As part of its continual quest for improvement, Coast IRB is in the process of achieving accreditation with the Association for the Accreditation of Human Research Protection Program (AAHRPP) which ensures high-quality human research protection programs in order to promote excellent, ethically sound research.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.